CompanyGraph
What stands out
- Valued far above the size of its business
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $1.78B, above the global median of $1.15B
- FinancialsAltman Z-Score 9.97: safe zone
- Interpretations2 currently firing — 2
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
What stands out
- Valued far above the size of its business
Financials view
Market Capitalization
1.78BUSDvs all stocks (USD)
Revenue (TTM)
81.26MUSDvs all stocks (USD)
Profit Margin
-126.33%vs Biotechnology peers
Beta
1.13xvs all stocks
52-Week Change
68.92%vs all stocks
Market Capitalization
1.78BUSDvs all stocks (USD)
Enterprise Value
1.42BUSDvs all stocks (USD)
Forward P/E
85.18xvs Biotechnology peers
Price to Sales (TTM)
21.90xvs Biotechnology peers
Price to Book (MRQ)
11.04xvs Biotechnology peers
Enterprise to Revenue
17.46xvs Biotechnology peers
Enterprise to EBITDA
-13.16xvs Biotechnology peers
Profit Margin
-126.33%vs Biotechnology peers
Operating Margin
-1956.73%vs Biotechnology peers
Return on Assets (TTM)
-15.78%vs Biotechnology peers
Return on Equity (TTM)
-42.02%vs Biotechnology peers
Revenue (TTM)
81.26MUSDvs all stocks (USD)
Revenue per Share (TTM)
1.08USDUpdated Jul 19, 2026Quarterly Revenue Growth
-91.10%vs Biotechnology peers
Gross Profit (TTM)
-54.46MUSDvs all stocks (USD)
EBITDA (TTM)
-107.79MUSDvs all stocks (USD)
Net Income (TTM)
-102.66MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
-91.12%vs Biotechnology peers
Operating Cash Flow (TTM)
-75.32MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-45.50MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
105.97MUSDFY2025 · Dec 31, 2025Operating Income
-92.53MUSDvs all stocks (USD)
Pre-tax Income
-79.75MUSDFY2025 · Dec 31, 2025Income Tax Expense
1.38MUSDFY2025 · Dec 31, 2025Net Income
-81.13MUSDFY2025 · Dec 31, 2025EBIT
-92.53MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-80.81MUSDFY2025 · Dec 31, 2025Research & Development
137.00MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
61.50MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
13.35MUSDFY2025 · Dec 31, 2025EPS (Basic)
-1.08USDFY2025 · Dec 31, 2025EPS (Diluted)
-1.08USDFY2025 · Dec 31, 2025Basic Shares Outstanding
75.40MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
75.40MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-81.13MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-40.00MUSDFY2025 · Dec 31, 2025Free Cash Flow
-41.52MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
41.16MUSDFY2025 · Dec 31, 2025Income Tax Paid
1.35MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-81.13MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
11.11MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
945.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
28.03MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
51.20MUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-23.65MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-26.51MUSDFY2025 · Dec 31, 2025Capital Expenditures
-1.52MUSDFY2025 · Dec 31, 2025Net Intangibles (CF)
-831.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-196.06MUSDFY2025 · Dec 31, 2025Sale of Investments
225.08MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
27.49MUSDFY2025 · Dec 31, 2025Common Stock Repurchase
-41.70MUSDFY2025 · Dec 31, 2025Other Financing Charges
-181.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
-36.89MUSDFY2025 · Dec 31, 2025Shares Outstanding
73.65MSharesUpdated Jul 19, 2026Float Shares
68.01MSharesUpdated Jul 19, 2026Shares Short
4.36MSharesUpdated Jul 19, 2026Short Ratio
5.69daysvs all stocks
Short % of Shares Outstanding
8.86%vs all stocks
% Held by Insiders
1.30%vs all stocks
% Held by Institutions
103.00%vs all stocks
Total Cash (MRQ)
364.73MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
5.00USDUpdated Jul 19, 2026Total Debt (MRQ)
17.04MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.1042xvs Biotechnology peers
Current Ratio (MRQ)
10.82xvs Biotechnology peers
Book Value per Share (MRQ)
2.19USDUpdated Jul 19, 2026Total Assets
346.53MUSDvs all stocks (USD)
Total Current Assets
248.77MUSDFY2025 · Dec 31, 2025Total Liabilities
78.03MUSDFY2025 · Dec 31, 2025Total Non-current Assets
97.76MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
35.71MUSDFY2025 · Dec 31, 2025Total Current Liabilities
42.32MUSDFY2025 · Dec 31, 2025Cash
8.97MUSDFY2025 · Dec 31, 2025Cash Equivalents
32.19MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
41.16MUSDFY2025 · Dec 31, 2025Other Short-term Investments
187.64MUSDFY2025 · Dec 31, 2025Accounts Receivable
4.64MUSDFY2025 · Dec 31, 2025Accounts Payable
4.40MUSDFY2025 · Dec 31, 2025Short-term Debt
3.47MUSDFY2025 · Dec 31, 2025Deferred Revenue
2.42MUSDFY2025 · Dec 31, 2025Other Current Liabilities
844.00KUSDFY2025 · Dec 31, 2025Long-term Debt
14.80MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
278.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
1.11BUSDFY2025 · Dec 31, 2025Retained Earnings
-953.16MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
268.50MUSDvs all stocks (USD)
52-Week Low
11.51USDUpdated Jul 19, 202652-Week High
29.75USDUpdated Jul 19, 202652-Week Change
68.92%vs all stocks
Beta
1.13xvs all stocks
50-Day MA
24.59USDUpdated Jul 19, 2026200-Day MA
23.69USDUpdated Jul 19, 2026Avg 10-Day Volume
529.38KSharesUpdated Jul 19, 2026Avg 30-Day Volume
630.61KSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-1.37USDUpdated Jul 19, 2026Other Income / Expense
-559.00KUSDFY2025 · Dec 31, 20252 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
Is this company growing?
Diagnostic
High R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Heavy R&D and stock pay, with the share count growing across six years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Valued far above the size of its businessSignificant
Price-to-Sales: 21.90Revenue Growth YoY: -0.91
Financial Health
Altman Z-Score 9.97: safe zoneNotable
Altman Z-Score: 9.97
High structural barrier to entryNotable
Barrier to Entry: 3.52
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $1.78B, above the global median of $1.15BNotable
Market cap (USD): 1,779,753,729Global Median: 1,146,734,693.424
Companies that share the same coordination system — how they create, deliver, or capture value.
Heron Neutron Medical Corp.
Tier 1ProductionApproval-Gated PipelineRule
Natco Pharma Ltd.
Tier 1ProductionApproval-Gated PipelineRule
BeBetter Med Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Precigen Inc.
Tier 1ProductionApproval-Gated PipelineRule
Ani Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Bausch Health Companies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Shyndec Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Stoke Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
PolyPeptide Group AG
Tier 1ProductionApproval-Gated PipelineRuleFlow
Chengdu Olymvax Biopharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Beam Therapeutics Inc.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Wave Life Sciences Ltd.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC
Hyliion Holdings Corp.
2 interpretationsMulti-Year Debt Decrease With Cash Near Total Debt And EquityHigh R&D Share With Multi-Year Share-Count Growth and Elevated SBC